Newton Centre Massachusetts based Pinteon Therapeutics is raising $70,085,725.00 in New Equity Investment.
Newton Centre, MA – According to filings with the U.S. Securities and Exchange Commission, Pinteon Therapeutics is raising $70,085,725.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Martin Jefson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Pinteon Therapeutics
Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease. Pinteons lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope which has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures.
To learn more about Pinteon Therapeutics, visit https://www.pinteon.com/about-us/
Contact:
Martin Jefson, President and Chief Executive Officer
917-607-0015
SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved